Kezar Life Sciences Voluntarily Halts Enrollment in Zetomipzomib Lupus Nephritis Trial

Sep 30, 2024, 12:24 PM

Kezar Life Sciences has announced the voluntary cessation of enrollment and dosing in its Phase 2b PALIZADE trial of Zetomipzomib for active lupus nephritis patients. This decision follows a recent review of emerging safety data by the Independent Data Monitoring Committee (IDMC), which included an assessment of four Grade 5 (fatal) serious adverse events (SAEs). The company is notifying the FDA and EMA but has not yet received a clinical hold letter.